Early SSRI treatment prevented the development of AD pathology (Aβ and/or Tau), spatial memory deficits and depression-like symptoms in amyloid (APPswe/PS1dE9) and triple-transgenic mouse models (3xTg-AD) [67, 68]. The gene discussed is MAPT; the disease is major depressive disorder.